利用常规健康数据分析支持药物警戒信号验证与优先级排序:EHDEN网络研究经验
该研究在VigiBase中针对仿制药厂商药品和16个预设不良事件进行统计信号检测,并在5天研究冲刺中利用10个EHDEN合作伙伴的常规健康数据对信号进行验证和优先级排序。
要点
- 常规健康数据分布式网络分析可在限定时间内支持信号验证与优先级排序。
- 分析耗时每信号数小时,其中执行阶段15-60分钟。
核心结论
- 在给定时间限制内,利用分布式网络的常规健康数据分析支持信号验证和优先级排序是可行的,并能影响决策。
- 在信号管理此阶段整合这些分析的成本效益仍需进一步研究。
研究设计与样本
- 在VigiBase中针对仿制药厂商药品和16个预设不良事件进行统计信号检测。
- 在为期5天的研究冲刺中,结合VigiBase、监管文件和科学文献信息,以及来自EHDEN 10个合作伙伴的常规健康数据描述性分析进行信号验证和优先级排序。
- 数据库来自英国、西班牙、挪威、荷兰和塞尔维亚,涵盖初级保健和/或医院记录。
主要发现
- 每个信号的设计、执行和结果解读耗时可达数小时,其中执行耗时15-60分钟。
- 常规健康数据的洞察为8个信号中的5个决策提供了信息。
- 3个信号被选入信号评估,其中2个决策得到常规健康数据洞察的支持。
临床怎么用
- 可利用多国分布式常规健康数据对药物警戒信号进行快速描述性分析,以辅助信号验证和优先级排序。
- 分析结果可提供可能的替代解释、潜在公共卫生和临床影响以及后续药物流行病学研究的可行性信息。
局限性
- 分析代码标准化、不良事件表型可用性(包括不同源词汇表之间的桥接)以及常规健康数据访问和使用的治理被确定为未来开发的重要方面。
- 在信号管理此阶段整合这些分析的成本效益需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Individual case reports are the main asset in pharmacovigilance signal management. Signal validation is the first stage after signal detection and aims to determine if there is sufficient evidence to justify further assessment. Throughout signal management, a prioritization of signals is continually made. Routinely collected health data can provide relevant contextual information but are primarily used at a later stage in pharmacoepidemiological studies to assess communicated signals. OBJECTIVE: The aim of this study was to examine the feasibility and utility of analysing routine health data from a multinational distributed network to support signal validation and prioritization and to reflect on key user requirements for these analyses to become an integral part of this process. METHODS: Statistical signal detection was performed in VigiBase, the WHO global database of individual case safety reports, targeting generic manufacturer drugs and 16 prespecified adverse events. During a 5-day study-a-thon, signal validation and prioritization were performed using information from VigiBase, regulatory documents and the scientific literature alongside descriptive analyses of routine health data from 10 partners of the European Health Data and Evidence Network (EHDEN). Databases included in the study were from the UK, Spain, Norway, the Netherlands and Serbia, capturing records from primary care and/or hospitals. RESULTS: Ninety-five statistical signals were subjected to signal validation, of which eight were considered for descriptive analyses in the routine health data. Design, execution and interpretation of results from these analyses took up to a few hours for each signal (of which 15-60 minutes were for execution) and informed decisions for five out of eight signals. The impact of insights from the routine health data varied and included possible alternative explanations, potential public health and clinical impact and feasibility of follow-up pharmacoepidemiological studies. Three signals were selected for signal assessment, two of these decisions were supported by insights from the routine health data. Standardization of analytical code, availability of adverse event phenotypes including bridges between different source vocabularies, and governance around the access and use of routine health data were identified as important aspects for future development. CONCLUSIONS: Analyses of routine health data from a distributed network to support signal validation and prioritization are feasible in the given time limits and can inform decision making. The cost-benefit of integrating these analyses at this stage of signal management requires further research.
引用
- Gauffin O, Brand JS, Vidlin SH, et al. Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study. Drug Saf. 2023. PMID: 37804398. doi:10.1007/s40264-023-01353-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。